Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.

@article{Corbacioglu2012DefibrotideFT,
  title={Defibrotide for the treatment of hepatic veno-occlusive disease in children after hematopoietic stem cell transplantation.},
  author={Selim Corbacioglu and Nancy A Kernan and Leslie Lehmann and Joel A Brochstein and Carolyn Revta and Stephan A. Grupp and Paul Martin and Paul G Richardson},
  journal={Expert review of hematology},
  year={2012},
  volume={5 3},
  pages={
          291-302
        }
}
Hepatic veno-occlusive disease (VOD) is a serious complication of stem cell transplantation in children. VOD is characterized by rapid weight gain, hepatomegaly, hyperbilirubinemia and ascites. The pathogenesis of VOD is thought to involve chemotherapy and radiation-induced damage to the sinusoidal endothelium, resulting in endothelial injury, microthrombosis, subendothelial damage and cytokine activation. These processes lead to concomitant progressive hepatocellular dysfunction and subsequent… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-5 of 5 citations

References

Publications referenced by this paper.
Showing 1-10 of 78 references

Defibrotide ( DF ) in the treatment of severe hepatic veno - occlusive disease ( VOD ) with multi - organ failure ( MOF ) : results of a treatment IND expanded access protocol

  • PG Richardson, A Smith, S Arai
  • Blood
  • 2010
1 Excerpt